KTKwan Hou Tang

Kwan Hou Tang

*This is an algorithmically generated author record based on publicly available information.

Kwan Hou Tang has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Gielenny M. Salem

    Graduate Institute of Microbiology and Public Health, College of Veterinary Medicine, National Chung Hsing University, Taichung City, Taiwan

    2 shared publications
  • Suan-Sin Foo

    Department of Microbial Sciences in Health, Cleveland Clinic, Cleveland, USA

    2 shared publications
  • Anne W. Rimoin

    Department of Epidemiology, Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles, CA, USA

    1 shared publication
  • Dallas Swendeman

    Department of Psychiatry & Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, USA

    1 shared publication
  • Débora Familiar-Macedo

    Laboratory of Virus-Host Interactions (LIVH), Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz)

    1 shared publication
  • Elizabeth Mayfield Arnold

    Department of Psychiatry, University of Kentucky College of Medicine, Lexington, USA

    1 shared publication

Latest Publications

  • Maternal-fetal health in arboviral diseases: clinical outcomes following prenatal dengue and chikungunya virus infections

    by Gielenny M. Salem, Kwan Hou Tang, Débora Familiar-Macedo, Shiao-Yng Chan, Karin Nielsen-Saines, Weiqiang Chen, Suan-Sin Foo

    SUMMARY: Arthropod-borne viruses (arboviruses) are an increasingly important cause of global infectious disease, yet their effects during pregnancy and early life remain incompletely understood. In the context of declining fertility and birth rates globally, infectious threats to successful pregnancy and neonatal health warrant greater attention. Dengue virus (DENV) and chikungunya virus (CHIKV), two of the most prevalent mosquito-borne viruses, are underrecognized contributors to maternal-fetal health. Although these infections rarely result in classical congenital syndromes, accumulating clinical, epidemiological, and experimental evidence indicates that prenatal exposure can impair placental function, drive maternal immune dysregulation, and influence fetal and neonatal immune development. This review summarizes current knowledge on the maternal, placental, and pediatric consequences of DENV and CHIKV infection during pregnancy. We outline the immunological features of the maternal-fetal interface and discuss how pregnancy-associated immune modulation shapes antiviral responses and placental homeostasis. We then review epidemiological and clinical evidence linking prenatal arboviral infection with adverse pregnancy outcomes, neonatal disease, and potential long-term neurodevelopmental effects. Mechanistic insights, including viral immune evasion, placental inflammation, and antibody-mediated immunopathology, are examined. Finally, we discuss clinical considerations for monitoring arboviral-exposed pregnancies and progenies, alongside emerging strategies to reduce maternal infection and improve neonatal outcomes.

  • Open Access

    Distinct inflammatory marker profiles of adolescents and young adults among the HIV risk, infection, and treatment spectrum

    by Huan Vinh Dong, Gielenny M. Salem, Tara Kerin, Kwan Hou Tang, Ruth Cortado, Myung Shin-Sim, Elizabeth Mayfield Arnold, Dallas Swendeman, Nicole H. Tobin, Anne W. Rimoin, et al.

    Youth living with or at HIV-risk exhibit distinct immune perturbations during HIV exposure, infection, and antiretroviral therapy (ART). Understanding immune perturbations is critical for development of tailored prevention and enhanced therapeutic strategies. We performed plasma proteomic profiling of 49 biomarkers using Luminex multiplex assay in 262 participants (mean age of 21.9 years), including healthy controls, high-risk youth without HIV (HRY), newly diagnosed youth living with HIV (NY), and previously diagnosed youth on ART for over 24 months (PY), and report distinct immune landscapes. Among HRY, we observe dysregulation of circulating interferon-driven inflammation. NY display overt systemic inflammation at diagnosis, which partially resolves but does not fully normalize within 24 months of ART. PY display largely normalized immune profiles, though circulating signatures consistent with residual checkpoint activation persist. Our results identify conserved and stage-specific, circulating inflammatory modulators and key transcriptional regulators delineating HIV susceptibility, progression, and long-term treatment responses.